FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

         (Mark One)
               X     Quarterly  Report  Pursuant  to  Section 13 or 15(d) 
                     of the Securities Exchange Act of 1934

                      For Quarter Ended: November 30, 1998
                                       OR
               _ Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                               Georgia 22-2408354
                (State or other jurisdiction of (I.R.S. Employer
               incorporation or organization) Identification No.)

          3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091-5625 
              (Address of principal executive offices) (Zip Code)
               


                  Registrant's telephone number: (770) 441-2051

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                                    Yes X No

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

       As of January 12, 1999: Common Stock, $. 10 Par Value - 7,457,405

<PAGE>

                                      IMMUCOR, INC.
                          Condensed Consolidated Balance Sheets
<TABLE>

                                                November 30                     May 31,
                                                    1998                         1998
                                                 (Unaudited)                  (Audited)
                                             ----------------             ---------------
<S>                                                  <C>                         <C>

ASSETS
Current assets:
  Cash and cash equivalents                        $3,973,203                 $15,816,217
  Short-term investments                              100,000                           0
  Accounts receivable, net                         18,083,540                  12,214,270
  Accounts receivable, other                          143,115                     695,430
  Inventories                                      13,275,730                   8,462,850
  Income taxes receivable                             326,212                      95,166
  Deferred income taxes                               375,164                     370,029
  Other assets                                      1,173,549                     447,661
                                              ----------------             ---------------
    Total current assets                           37,450,513                  38,101,623

Long-term investment                                1,000,000                   1,000,000

Property and equipment, at cost                    19,160,198                  10,505,766
  less accumulated depreciation                    (4,770,662)                 (4,486,974)
                                              ----------------             ---------------
                                                   14,389,536                   6,018,792

Other assets, net                                   3,071,121                     801,779

Cash value of life insurance                        1,557,125                           0

Excess of cost over net tangible
  assets acquired, net                             27,619,695                  11,622,082
                                              ----------------             ---------------

                                                  $85,087,990                 $57,544,276
                                              ================             ===============

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Current portion of long-term obligations           $507,619                    $359,325
  Accounts payable                                  5,949,194                   3,069,973
  Income taxes payable                                232,922                     359,598
  Accrued salaries and wages                        4,169,240                     862,550
  Other accrued liabilities                         1,965,917                     501,739
                                              ----------------             ---------------
    Total current liabilities                      12,824,892                   5,153,185

Long-term obligations                              29,033,507                   8,911,727

Deferred income taxes                               1,283,684                   1,046,814

Other liabilities                                   2,640,000                           0

Shareholders' equity:
  Common stock, $.10 par value                        752,519                     807,881
  Additional paid-in capital                       16,940,063                  22,079,468
  Retained earnings                                23,281,776                  21,937,697
  Accumulated other comprehensive loss             (1,668,451)                 (2,392,496)
                                              ----------------             ---------------

    Total shareholders' equity                     39,305,907                  42,432,550
                                              ----------------             ---------------

                                                  $85,087,990                 $57,544,276
                                              ================             ===============


</TABLE>


See accompanying notes.

<PAGE>

                                  IMMUCOR, INC.
                   Condensed Consolidated Statements of Income
                                   (Unaudited)

<TABLE>

                                                    Three Months Ended                    Six Months Ended
                                          November 30,        November 30,        November 30,        November 30,
                                              1998                1997                1998                1997

                                         ----------------    ---------------     ----------------    ----------------
<S>                                             <C>                 <C>                 <C>               <C>

Net sales                                    $13,665,490        $10,192,109          $24,023,955         $19,465,588
Cost of sales                                  6,316,043          4,761,634           10,968,726           8,609,015
                                         ----------------    ---------------     ----------------    ----------------
Gross profit                                   7,349,447          5,430,475           13,055,229          10,856,573

Research and development                         297,345            208,079              587,372             469,378
Selling and marketing                          2,343,582          1,740,972            4,291,329           3,528,023
Distribution                                     735,198            603,382            1,298,149           1,167,606
General and administrative                     2,063,679          1,766,287            3,793,508           3,414,162
Merger-related expenses                          312,361                  0              312,361                   0
Amortization expense                             239,098            140,690              381,234             302,519
                                         ----------------    ---------------     ----------------    ----------------
Total operating expenses                       5,991,263          4,459,410           10,663,953           8,881,688
                                         ----------------    ---------------     ----------------    ----------------

Income from operations                         1,358,184            971,065            2,391,276           1,974,885

Interest income                                  110,901            195,123              285,933             398,496
Interest expense                                (252,392)          (152,486)            (386,479)           (319,101)
Other income (expense)                            38,673              3,703               75,427              (9,972)
                                         ----------------    ---------------     ----------------    ----------------
Total other                                     (102,818)            46,340              (25,119)             69,423
                                         ----------------    ---------------     ----------------    ----------------

Income before income taxes                     1,255,366          1,017,405            2,366,157           2,044,308

Income taxes                                     539,298            470,998            1,022,078             940,246
                                         ----------------    ---------------     ----------------    ----------------

Net income                                      $716,068           $546,407           $1,344,079          $1,104,062
                                         ================    ===============     ================    ================

Earnings per share:

     Basic and diluted                             $0.09              $0.07                $0.17               $0.14
                                         ================    ===============     ================    ================

     Diluted                                       $0.09              $0.06                $0.17               $0.13
                                         ================    ===============     ================    ================


Weighted average shares outstanding:

     Basic                                     7,672,725          8,098,797            7,837,394           8,089,561
                                         ================    ===============     ================    ================

     Diluted                                   7,939,810          8,568,731            8,111,689           8,484,729
                                         ================    ===============     ================    ================

</TABLE>


See accompanying notes.
<PAGE>

                                     IMMUCOR, INC.
                    Condensed Consolidated Statements of Cash Flows
                                      (Unaudited)

<TABLE>

                                                               Six Months Ended
                                                          November 30,    November 30,
                                                           1998               1997
                                                       -------------      --------------
<S>                                                            <C>              <C>

OPERATING ACTIVITIES:
  Net income                                             $1,344,078          $1,104,062
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                          721,694             703,755
      Amortization                                          381,234             302,726
      Changes in assets and liabilities:
        Accounts receivable                              (2,292,611)           (652,882)
        Accounts receivable, other                          552,315            (130,922)
        Income tax receivable                                (9,046)              1,196
        Inventories                                      (1,127,536)         (1,080,409)
        Other current assets                                163,603            (154,385)
        Accounts payable                                  1,643,098             130,184
        Income taxes payable                               (105,686)             17,448
        Other current liabilities                           618,935             274,597
                                                       -------------      --------------

Cash provided by operating activities                     1,890,078             515,370

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment       (1,472,477)           (779,258)
  Cash paid for acquisition, net of cash acquired       (25,102,864)                  0
  Decrease in other assets                               (2,116,909)             29,771
                                                       -------------      --------------

Cash used in investing activities                       (28,692,250)           (749,487)

FINANCING ACTIVITIES:
  Borrowings under line of credit agreements             20,600,000            (101,986)
  Repayment of notes payable                               (838,371)           (357,419)
  Exercise of stock options and warrants                  1,259,194              95,811
  Purchase and retirement of stock  (721,200 shares)     (6,453,961)                  0
                                                       -------------      --------------

Cash provided by (used in) financing activities          14,566,862            (363,594)

EFFECT OF EXCHANGE RATE CHANGES ON CASH                     392,296            (286,006)
                                                       -------------      --------------

DECREASE IN CASH
  AND CASH EQUIVALENTS                                  (11,843,014)           (883,717)

CASH AND CASH EQUIVALENTS
  AT BEGINNING OF PERIOD                                 15,816,217          15,718,234
                                                       -------------      --------------

CASH AND CASH EQUIVALENTS
 AT END OF PERIOD                                        $3,973,203         $14,834,517
                                                       =============      ==============

Noncash investing and financing activities:
  Fair value of assets acquired, net of cash            $17,757,750
  Cost in excess of assets acquired                      16,523,461
  Liabilities assumed                                    (9,178,347)
                                                       
                                                       =============
  Net cash paid for acquisition                         $25,102,864
                                                       =============
</TABLE>

<PAGE>
 IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1998, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been  included.  Operating  results for the six month  period
ended November 30, 1998 are not  necessarily  indicative of the results that may
be expected for the year ending May 31, 1999. For further information,  refer to
the  consolidated  financial  statements and footnotes  thereto  included in the
Company's Annual Report on Form 10-K for the year ended May 31, 1998.

2.       INVENTORIES
Inventories are stated at the lower of first-in, first-out cost or market:
<TABLE>

                                                      As of                        As of
                                                November 30, 1998              May 31, 1998
                                              -----------------------      ----------------------
<S>                                                      <C>                           <C>

Raw materials and supplies                                $4,379,435                  $2,668,444
Work in process                                            1,029,546                     762,475
Finished goods                                             7,866,749                   5,031,931
                                              =======================      ======================
                                                         $13,275,730                  $8,462,850
                                              =======================      ======================
</TABLE>

3.     Earnings per share
In 1997, the Financial  Accounting  Standards Board ("FASB") issued Statement of
Financial  Accounting  Standards No. 128, Earnings per Share ("Statement  128").
Statement 128 replaced the calculation of primary and fully diluted earnings per
share with basic and diluted  earnings per share.  Unlike  primary  earnings per
share,  basic  earnings  per share  excludes  any  dilutive  effects of options,
warrants and convertible securities.  Diluted earnings per share is very similar
to the previously  reported fully diluted  earnings per share.  All earnings per
share  amounts  for all  periods  have been  presented,  and where  appropriate,
restated to conform to the Statement 128 requirements.  The following table sets
forth the computation of basic and diluted earnings per share.

<TABLE>
                                                         Three Months Ended                Six Months Ended
                                                    November 30,     November 30,     November 30,     November 30,
                                                        1998             1997             1998             1997

                                                   ---------------- ---------------  ---------------- ---------------
<S>                                                      <C>              <C>               <C>             <C>

Numerator for basic and diluted earnings per share:
  Income available to common shareholders                 $716,068        $546,407        $1,344,079      $1,104,062
                                                   ================ ===============  ================ ===============

Denominator:
  For basic earnings per share - weighted
  average basis                                          7,672,725       8,098,797         7,837,394       8,089,561

  Effect of dilutive stock options and warrants            267,085         469,934           274,295         395,168
                                                                                     ---------------- ---------------
                                                   ---------------- ---------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                       7,939,810       8,568,731         8,111,689       8,484,729
                                                   ================ ===============  ================ ===============

Basic earnings per share                                     $0.09           $0.07             $0.17           $0.14
                                                   ================ ===============  ================ ===============

Diluted earnings per share                                   $0.09           $0.06             $0.17           $0.13
                                                   ================ ===============  ================ ===============

</TABLE>
<PAGE>

4.    domestic and foreign operations
Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):

<TABLE>
                          ----------------------------------------------------------------------------------------------------
                                                     For the Three Months Ended November 30, 1998
                          ----------------------------------------------------------------------------------------------------
<S>                          <C>           <C>           <C>            <C>          <C>           <C>              <C>

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated             $7,550        $2,656        $1,884        $1,029          $546                       $13,665
customers                                                                                       $         -
   Affiliates                1,069            78             -            26             -        (1,173)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                  8,619         2,734         1,884         1,055           546        (1,173)         13,665

Income from operations         287           424           268           283            85            11           1,358

</TABLE>
<TABLE>

                          ----------------------------------------------------------------------------------------------------
                                                     For the Three Months Ended November 30, 1997
                          ----------------------------------------------------------------------------------------------------
<S>                          <C>           <C>           <C>            <C>          <C>           <C>              <C>
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated             $5,114        $2,411        $1,457        $1,008          $202                       $10,192
customers                                                                                       $         -
   Affiliates                  791            62             -            42             -          (895)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                  5,905         2,473         1,457         1,050           202          (895)         10,192

Income from operations         162           306           129           319            33            22             971


</TABLE>
<TABLE>
                          ----------------------------------------------------------------------------------------------------
                                                 As of and for the Six Months Ended November 30, 1998
                          ----------------------------------------------------------------------------------------------------
<S>                          <C>           <C>           <C>            <C>          <C>           <C>              <C>
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated            $12,498        $5,079        $3,398        $2,216          $833                       $24,024
customers                                                                                       $         -
   Affiliates                2,047           166             -            93             -        (2,306)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 14,545         5,245         3,398         2,309           833        (2,306)         24,024

Income from operations         549           760           390           623            92           (23)          2,391

Deferred tax assets            347                                                                    28             375
                                        -             -             -             -
Long-lived assets           49,972         4,282         2,543         7,547           654       (17,361)         47,637

Total       identifiable    74,836         8,701        10,714         9,024         2,752       (20,939)         85,088
assets

Net assets                  40,470         5,101          (708)        1,541           876        (7,974)         39,306

</TABLE>
<TABLE>
                          ----------------------------------------------------------------------------------------------------
                                                 As of and for the Six Months Ended November 30, 1997
                          ----------------------------------------------------------------------------------------------------
<S>                          <C>           <C>           <C>            <C>          <C>           <C>              <C>
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
   Unaffiliated             $9,523        $4,683        $2,801        $2,079          $380                       $19,466
customers                                                                                       $         -
   Affiliates                1,844           147            18            70             -        (2,079)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 11,367         4,830         2,819         2,149           380        (2,079)         19,466

Income from operations         482           525           264           659            52            (7)          1,975

Deferred tax assets            348                                                                    33             381
                                        -             -             -             -
Long-lived assets           19,664         4,298         2,356         8,315           372       (15,340)         19,665

Total       identifiable    46,866         9,587         9,943        10,027          1191       (19,685)         57,929
assets

Net assets                  44,691         4,131        (1,019)        1,271           114        (7,397)         41,791


</TABLE>

<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS  (continued)
The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,213,000  and $960,000 for the three months ended  November 30,
1998 and 1997,  respectively  and  $2,043,000  and $1,740,000 for the six months
ended November 30, 1998 and 1997,  respectively.  The Company's German operation
made net export sales to  unaffiliated  customers of  approximately  $86,000 and
$100,000 for the three months ended November 30, 1998 and 1997, respectively and
$374,000  and  $375,000  for the six months  ended  November  30, 1998 and 1997,
respectively.  The  Company's  Canadian  operation  made  export  net  sales  to
unaffiliated  customers  of  approximately  $596,000  and $706,000 for the three
months  ended  November  30,  1998 and 1997,  respectively  and  $1,407,000  and
$1,461,000  for the six months ended  November 30, 1998 and 1997,  respectively.
Product sales to affiliates are valued at market prices.

5.       COMPREHENSIVE INCOME
In June 1997, the FASB issued  Statement of Financial  Accounting  Standards No.
130, Reporting Comprehensive Income ("Statement 130"). Statement 130 establishes
new  standards for the  reporting  and display of  comprehensive  income and its
components  (revenues,  expenses,  gains,  and  losses) in a full set of general
purpose  financial  statements.  These  new  standards  require  that all  items
recognized  as  components  of  comprehensive  income be reported in a financial
statement  that is  displayed  with  the  same  prominence  as  other  financial
statements. Statement 130 is effective for fiscal years beginning after December
15,  1997.  The  Company  adopted  Statement  130 on  June 1,  1998  and has not
presented  a  statement  of  comprehensive  income  because  the  effect  of the
components of comprehensive income is not material to its consolidated financial
statements.  For the three  months  ended  November  30,  1998 and  1997,  total
comprehensive  income was $1,493,800 and $1,034,597,  respectively,  and for the
six months  ended  November  30, 1998 and 1997,  was  $2,068,124  and  $812,018,
respectively,  which is comprised of net income and other  comprehensive  income
(losses).  Other  comprehensive  income for the three months ended  November 30,
1998 and 1997 was $777,732 and $488,190,  respectively  and other  comprehensive
income (loss) for the six months ended  November 30, 1998 and 1997 were $724,045
and  ($292,044),  respectively,  and  consisted  of income  (losses)  on foreign
currency  translation  adjustments.  Accumulated other  comprehensive loss as of
November  30,  1998 was  ($1,668,451).  The  balance  consists  of net losses on
foreign  currency  translation   adjustments  and  has  been  disclosed  in  the
shareholders' equity section of the condensed consolidated balance sheet.

6.   ACCOUNTS RECEIVABLE, OTHER
In fiscal 1997, Mr. Josef Wilms,  the former  president of the Company's  German
subsidiary, Immucor GmbH, borrowed, prior to his resignation,  $300,000 from the
Company at 6% interest,  secured by his warrants to purchase  143,750  shares of
the  Company's  Common  Stock.  At May 31,  1998 the loan  receivable  including
interest  totaled  $167,000,  and at November  30, 1998 the loan and all accrued
interest was fully paid.

In July 1997,  management  of the Company  discovered  that Mr. Wilms had caused
Immucor GmbH to make unauthorized  loans to him since 1994. The amounts advanced
were documented in the records of Immucor GmbH, including interest rates ranging
from 7.75% to 9.5%, and were  generally paid down by the end of each  accounting
period,  but  were  not  disclosed  to the  Company's  management.  The  largest
aggregate  amounts  outstanding  under the  Immucor  GmbH loans were  $29,600 in
fiscal 1994,  $290,000 in fiscal 1995, $669,000 in fiscal 1996 and $1,311,000 in
fiscal 1997. At May 31, 1998 the amount receivable was approximately  $1,300,000
and at November 30, 1998 the loan receivable balance was approximately $143,000.

Mr. Wilms and his family have granted liens on certain property owned by them to
collateralize  the loans from the Company.  The Company believes it has adequate
collateral to extinguish the remaining debt and, with Mr. Wilm's assistance,  is
arranging for the liquidation of this collateral.


<PAGE>



7.    ACQUISITION OF GAMMA BIOLOGICALS, INC.
Pursuant to a definitive  merger  agreement dated  September 21, 1998,  Immucor,
through a newly formed subsidiary ("Gamma  Acquisition  Corporation"),  acquired
94.3% of the issued and outstanding  shares of Gamma  Biologicals,  Inc. ("Gamma
Biologicals").   Immucor   purchased   the  shares   from   Gamma   shareholders
("Shareholders")  for a cash  tender  offer  of  $5.40  per  share  for a  total
transaction  value  of  $24,322,753  ("Purchase  Price"),   subject  to  certain
adjustments.  According to the depository for the offer,  4,361,110  shares were
tendered  pursuant to the offer and Immucor  purchased all shares tendered.  The
Purchase Price was determined  through arm's length  negotiations and $5,000,000
of the  Purchase  Price was paid in cash and the  remaining  $19,322,753  of the
Purchase  Price was funded by a $20,000,000  loan from Wachovia Bank of Georgia,
N.A., a U.S. commercial bank, to Gamma Acquisition Corporation.  On November 4,
1998, the Company entered into an interest rate swap agreement with a notional
amount of $15,000,000 maturing on the same date of the loan which converts the
loan's floating rate to a fixed rate.

Immucor  effected  the  merger  of  Gamma  Acquisition  Corporation  into  Gamma
Biologicals on October 30, 1998. In the merger, each remaining outstanding share
of Gamma  Biologicals  was converted into the right to receive $5.40 net in cash
and Gamma Biologicals became a majority-owned subsidiary of Immucor.

Located in  Houston,  Texas,  Gamma  Biologicals  manufactures  and sells a wide
variety of in-vitro diagnostic  reagents to blood donation centers,  transfusion
departments of hospitals, medical laboratories and research institutions through
a direct sales force and  distributor  network.  The company  accounted  for the
transaction as a purchase business combination. The results of the operations of
Gamma  Biologicals  since October 27, 1998 are included in the 1998 Consolidated
Statements of Income.  Goodwill  which  represents  the excess of costs over net
assets acquired will be amortized on a straightline basis over 30 years.

The preliminary purchase price allocation is as follows:


Current assets                                                       $8,590,559
Property, plant and equipment, net                                    7,535,909
Other assets                                                          2,320,447
Excess of costs over net assets acquired - Goodwill                  16,523,461
Less:  Liabilities assumed                                          (8,308,458)
                                                               -----------------

Purchase price                                                      $26,661,918
                                                               =================



The pro forma unaudited  results of operations for the six months ended November
30,1998 and November 30, 1997, assuming  consummation of the purchase as of June
1, 1997,  including  financing from the proceeds of a bank loan and ignoring any
cost-saving initiatives are presented below:

<TABLE>

                                                 Six Months Ended            Six Months Ended
                                                November 30, 1998            November 30, 1997
                                              -----------------------      ----------------------
<S>                                                     <C>                           <C>

Net sales                                                $31,063,428                 $28,905,080
Net income                                                   355,293                   1,108,908

Net income per common share:
     Basic                                                       .05                         .14
     Diluted                                                     .04                         .13

</TABLE>

8.    ACQUISITION OF CANADIAN DISTRIBUTION RIGHTS
On September 1, 1998 the Company acquired the Canadian  distribution  rights for
the Company's  complete line of reagents from its Canadian  distributor  Immucor
Canada,  Inc. for cash  consideration  of $1.7  million and related  acquisition
costs for a total cost of $2,116,909.  The rights have been  classified as other
assets and are being amortized over the 10-year term of the agreement.


<PAGE>



                                  IMMUCOR, INC.

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
 of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1998.

Financial Condition and Liquidity:

    During the six months  ended  November  30, 1998 the Company  increased  its
profitability, maintained positive working capital and had no significant change
in the cash from  operating  activities.  As of November 30, 1998, the Company's
cash position  totaled  $3,973,203.  For the six months ended November 30,
1998, the Company  generated  cash from  operating  activities of $1,890,078 and
repaid $838,371 of bank debt primarily in Germany and Canada.

    On  October  27,  1998,  the  Company  acquired  94.3%  of  the  issued  and
outstanding common stock of Gamma  Biologicals,  Inc. for a cash tender offer of
$5.40 per share and certain  transaction costs for a total value of $26,661,918.
Approximately  $5,000,000  of the  purchase  price  was  paid  in  cash  and the
remainder was funded by a $20,000,000  loan from the Company's lead bank, use of
Gamma Biologicals, Inc.'s cash and assuming other liabilities.

     In June 1997,  the Company  authorized a program to repurchase up to 10% of
its common stock in the open market.  During the six month period ended November
30,  1998 the Company  repurchased  approximately  721,000  shares of its common
stock for  $6,453,961  under  the  program.  To date  824,000  shares  have been
purchased  under the 1997  program.  On August 26, 1998,  the Board of Directors
authorized  the Company to repurchase up to an additional  800,000 shares of its
common stock. The exercise of  approximately  168,000 stock options and warrants
provided $1,259,194 in cash.

     Management  believes that the Company's  current cash and cash  equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

    Net sales for the three months ended November 30, 1998 totaled  $13,665,000,
an increase of $3,473,000 (34%) over last year's $10,192,000. Current year three
month  results  included  $1,694,000 in net sales from Gamma  Biologicals,  Inc.
acquired  on October 27,  1998 (see  Financial  Condition  and  Liquidity).  The
remaining  increase in sales was generated  equally in the US and Europe and was
primarily  due  to  instrumentation  sales.  The  Company  generated  instrument
revenues of $1,583,000.  Sales by the Company's European subsidiaries  increased
23% over last  year's  total of which 5% was due to  favorable  rates of foreign
exchange  in Europe as compared to the prior  period.  For the six months  ended
November 30, 1998, net sales were  $24,024,000  (including  Gamma's  $1,694,000)
compared to $19,466,000 in the prior year.


<PAGE>



Gross profit

    As a percent of sales,  gross profit for the three months ended November 30,
1998 totaled  53.8%  versus  53.3% for the same period in 1997.  The increase in
gross profit  margin was  primarily  caused by increased  end customer  sales at
higher  margins.  Also,  the  Company  has begun to  recognize  the  benefit  of
increased higher margin reagent sales associated with instrument placements this
quarter.  The Company  expects  continued  increases in reagent  sales in future
quarters due to the placement of these  instruments which will positively affect
gross profit dollars.

Operating expenses

    When compared to the prior year three and six month periods ended  November
30,  1998  research  and  development   costs  increased  $89,000  and  $118,000
respectively with $90,000 of the additional  research expense resulting from the
acquisition of Gamma Biologicals, Inc. (see Financial Condition and Liquidity).

    Selling  and  marketing  expenses  for the  three  and  six  month  periods
increased $603,000 and $763,000 respectively as compared to the same period last
year. Part of the increase was due to the inclusion of Gamma  Biologicals,  Inc.
($366,000).  The  remainder of the  increase is  primarily  due to the effect of
higher payroll  expense due to additional  personnel  required for the Company's
instrumentation strategy.

    Distribution  expenses  increased  $132,000  for the three month  period and
$131,000  for the six month period due to the  inclusion  of Gamma  Biologicals,
Inc. ($102,000) and increased shipping activity.

     General and  administrative  expenses for the three and six month  periods
increased  $298,000  and  $380,000  respectively  with  $191,000  of  additional
expenses  resulting from purchase of Gamma  Biologicals,  Inc. and the remainder
due to higher expenses in Europe as we expand  operations in Spain,  Italy,  and
Portugal.

    Merger-related   expenses   are   one-time expenses  related  to  the Gamma
Biologicals Inc. acquisition.


Interest income

    Interest income  decreased  $84,000 for the quarter and $112,000 for the six
month  period due to lower cash  balances as compared to last year caused by the
purchase  of  Gamma  Biologicals,  Inc.  funded  partially  by the use of of the
Company's cash and the purchase of treasury stock (see Financial  Conditions and
Liquidity).

Interest expense

    When  compared  to the prior  year  three and six  month  period,  interest
expense  increased  $100,000  and  $67,000.  This is a result of the purchase of
Gamma Biological, Inc. which was financed with the proceeds of a bank loan.

Other income(expense)

    Other  income  increased  for the  $35,000  for the three  month  period and
$84,000  for the six month  period  due to a gain on sale of  certain  assets in
Europe during the current period compared to higher currency  transaction losses
incurred in Europe last year.

Income taxes

    Income tax expense as a percent of pretax income, decreased during the three
month period ended August 31, 1998 and six month period ended  November 30, 1998
due to lower taxes  provided in Germany and the United States as compared to the
prior period.  This is a result of the Company's  ongoing  implementation of tax
planning strategies.

Year 2000

     The  Company is aware of the issues  that many  companies  will face as the
year 2000  approaches.  In order to become year 2000 compliant,  the Company has
set up a project team to address the issue and has taken the following steps:

    Impact  Assessment-  Instances where electronics are used in the Company and
the associated  potential risks have been identified.  The Company believes that
non-information  technology  systems  and its  products  are  not  significantly
impacted.  However,  internal business information software is affected and will
require program changes in order to become year 2000 compliant.

    Third  Party  Impact  Assessment  - The  Company  has  begun to  verify  the
readiness of its significant suppliers and customers through the distribution of
a  questionnaire.  Although this process is not complete,  based on  information
available,  the  Company  has no reason to believe  that any year 2000  problems
encountered  by customers  and suppliers  will have a significant  effect on the
Company's  operations.  The  Company  estimates  that  this  assessment  will be
completed by March 1999.

    Project  Plan - Based on the impact  assessment,  the need to make  software
program changes to the Company's internal business information software has been
identified.  In Europe,  minor software  program changes to existing systems are
being made at a nominal cost making them year 2000  compliant  before the summer
of 1999. In North America,  since the Company had already planned to implement a
new enterprise wide internal business  information  software system by September
1999, the need to make software  changes to the existing system are for the most
part not  required.  The  Company  has entered  into an  agreement  with a major
software  provider for an enterprise wide business  software system that is year
2000 compliant.  The Company's implementation plan is to install the software by
March 1999,  test and modify by October 1999 and be operating by November  1999.
The  Company  is  currently  setting  milestone   completion  dates  during  the
implementation period and will be monitoring progress closely.

     Contingency  Plan  -  The  risk  the  Company  faces  is  a  delay  in  the
implementation of the new internal business information software. The Company is
uncertain what the costs  associated with a delay would be or the related impact
on operations,  liquidity and financial condition.  Because of this, the Company
has in  place  a  contingency  plan  which  would  be  put  into  effect  should
implementation milestones not be met. If by April 1999, it is determined that an
October 1999 testing and modification milestone cannot be completed, the Company
will begin to make  program  modifications  to the  existing  internal  business
software.  The  Company  estimates  that all  modifications  and  testing can be
completed  within  two  months  at a cost of less  than  $20,000  which  will be
expensed as incurred. Expenses to date are nominal.

    The Company  believes that it is diligently  addressing  the year 2000 issue
and expects  that  through its actions  year 2000  problems  are not  reasonably
likely to have a material adverse effect on the Company's operations.  There can
be no assurance that such problems will not arise.

<PAGE>

PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

              27     Financial data schedule.
              10.1   Loan Agreement between Immucor, Inc. and Wachovia Bank,
                          National Association dated October 27, 1998.
                           


         (b) On November 10, 1998,  the Company  filed a Form 8-K dated  October
         27, 1998,  relating to Item 2, the  acquisition  of Gamma  Biologicals,
         Inc.

 SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                                   IMMUCOR, INC.
                                  (Registrant)



Date:  January 14, 1999








/s/  Edward L. Gallup          Edward L. Gallup, President
----------------------------







/s/  Steven C. Ramsey          Steven C. Ramsey, Senior Vice President - Finance
-----------------------------  (Principal Accounting Officer)